Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab
Foss, Francine Kim, Youn H Scarisbrick, Julia Akilov, Oleg Ristuccia, Robert Dwyer, Karen Wu, Wende Bagot, Martine
Foss, Francine
Kim, Youn H
Scarisbrick, Julia
Akilov, Oleg
Ristuccia, Robert
Dwyer, Karen
Wu, Wende
Bagot, Martine
Affiliation
Other Contributors
Publication date
2025-02-02
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Purpose: Mogamulizumab demonstrated improved outcomes vs. vorinostat across a range of disease and patient characteristics in patients with mycosis fungoides or Sézary syndrome in the MAVORIC trial.
Materials and methods: This post-hoc analysis further examined MAVORIC data to assess factors associated with long-term response (ORR >12 months), time to next treatment (TTNT), and impact of concomitant steroid use, lymphopenia, and mogamulizumab-associated rash (MAR) on patient response.
Results: A higher proportion of patients achieved ORR lasting ≥4, 6, 8, or 12 months in the mogamulizumab vs. vorinostat arm. Long-term response was also observed in mogamulizumab-treated patients with more advanced disease (stage IVA1 [17/20], B2 blood involvement [18/20], and SS [14/20]). PFS was significantly longer (9.4 vs. 3.1 months; p < 0.0001) in mogamulizumab vs. vorinostat-treated patients taking concomitant steroids. Mogamulizumab-treated patients experienced longer TTNT vs. vorinostat. Lymphopenia and MAR were associated with response to mogamulizumab.
Conclusions: MAVORIC demonstrated greater efficacy with mogamulizumab vs. vorinostat in relapsed/refractory patients with CTCL, including those with more advanced disease. Concomitant steroid use improved ORR and PFS but did not impact vorinostat outcomes. Overall responses occurred more frequently in mogamulizumab-treated patients that developed lymphopenia than those that did not. A higher percentage of patients with MAR had an overall response than those without MAR.
Citation
Foss F, Kim YH, Scarisbrick J, Akilov O, Ristuccia R, Dwyer K, Wu W, Bagot M. Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab. J Dermatolog Treat. 2025 Dec;36(1):2438794. doi: 10.1080/09546634.2024.2438794. Epub 2025 Feb 2.
Type
Article